Mail

MESO - Mesoblast Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

6.82

-0.03 (-0.51%)

As of 2:10PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	7.10
Open	6.95
Bid	6.81 x 1100
Ask	6.84 x 800
Day's Range	6.76 - 6.98
52 Week Range	3.35 - 8.78
Volume	26,512
Avg. Volume	59,845

Market Cap	691.453M
Beta (3Y Monthly)	1.14
PE Ratio (TTM)	N/A
EPS (TTM)	-0.91
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	12.33

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswire
Mesoblast Corporate Update: Analyst Call
NEW YORK, Sept. 09, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will provide a corporate update during an.
GlobeNewswire
Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain
AACHEN, Germany, and MELBOURNE, Australia, Sept. 09, 2019 -- Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in.
GlobeNewswire
Mesoblast Reports 2019 Full Year Results
NEW YORK and MELBOURNE, Australia, Aug. 29, 2019 -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today reported strong operational progress and financial highlights for the.
GlobeNewswire
Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019
NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host a webcast.
GlobeNewswire
FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD
NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, announced today.
GlobeNewswire
Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial
NEW YORK, Aug. 14, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it intends to provide.
GlobeNewswire
Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer
ASX: MSB), global leader in cellular medicines for inflammatory diseases, is pleased to announce the appointment of Dr Fred Grossman as Chief Medical Officer (CMO), based in New York. Dr Grossman brings a wealth of commercial experience gained from numerous leadership roles at global pharmaceutical companies. Dr Grossman has over 20 years of industry experience, and has held key leadership positions at major global pharmaceutical companies, including Eli Lilly, Johnson & Johnson (J&J), Bristol Myers Squibb (BMS), Sunovion, and Glenmark. During his career, he has managed global clinical development, pharmacovigilance, medical affairs and clinical operations for innovative product development, as well as United States Food and Drug Administration (FDA) approvals and post-market support for numerous blockbuster, specialty and generic products. Dr Grossman has led and built teams in the United States, Europe and Japan with responsibility for global medical affairs, global clinical development, health economics & outcomes research (HEOR) and global drug safety.
GlobeNewswire
Mesoblast Quarterly Cash Flow Report
MELBOURNE, Australia and NEW YORK, July 31, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its operational highlights and its quarterly cash flows for the.
Simply Wall St.
Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market?
If you're interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share...
GlobeNewswire
Circulation Research Special Article Highlights Potential Of Mesoblast Cell Therapy In Treatment Of Advanced Heart Failure
NEW YORK, July 25, 2019 -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that premier cardiovascular journal Circulation Research has published a Special Article.
Simply Wall St.
If You Had Bought Mesoblast (ASX:MSB) Stock Five Years Ago, You'd Be Sitting On A 69% Loss, Today
Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...
Motley Fool
Why Teva Pharmaceutical Industries, Mesoblast, and New Gold Jumped Today
Find out how a combination of factors helped these stocks defy a down market.
Benzinga
Mesoblast Trades Higher After Heart Failure Cell Therapy Receives Orphan Drug Status
Mesoblast Limited (NASDAQ: MESO ) product rexlemestrocel-L has received Orphan Drug Destination from the U.S. Food and Drug Administration for prevention of gastrointestinal bleeding in patients with left ...
GlobeNewswire
Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices
NEW YORK and MELBOURNE, Australia, June 24, 2019 -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced today.
GlobeNewswire
High Economic Burden in Children With Steroid Refractory Acute Graft Versus Host Disease
Mesoblast Presents Health Economics and Outcomes Research Data at 24th European Hematology Association Congress MELBOURNE, Australia; and NEW YORK, June 18, 2019 -- Mesoblast.
GlobeNewswire
Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease
ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced that it will host a virtual symposium to discuss Mesoblast’s product candidate, remestemcel-L, in steroid refractory acute graft versus host disease (aGVHD) in children, and to include Dr. Susan E. Prockop, a key opinion leader with significant expertise and experience in treating pediatric patients with this life threatening disease. Dr. Prockop is a pediatric oncologist specializing in bone marrow and stem cell transplantation at Memorial Sloan Kettering Cancer Center in New York.
GlobeNewswire
Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain
NEW YORK and MELBOURNE, Australia, June 11, 2019 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd..
GlobeNewswire
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019
MELBOURNE, Australia and NEW YORK, May 30, 2019 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported its financial results and operational highlights for the nine months.
Zacks
Mesoblast Starts Rolling BLA Submission for Remestemcel-L
Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.
GlobeNewswire
Mesoblast Financial Results Webcast for Period Ended March 31, 2019
MELBOURNE, Australia and NEW YORK, May 30, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the period ended March 31, 2019 in a webcast.
GlobeNewswire
Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease
The FDA has agreed to a rolling review of the BLA which enables individual components to be submitted and reviewed on an ongoing basis rather than waiting for all sections to be completed. The rolling process will provide opportunity for ongoing communication, and during this process the Company expects it will be able to adequately address any substantial matters raised by the FDA.
GlobeNewswire
Mesoblast Keynote Presentations to Feature at 2019 Annual Meeting of the International Society for Cell and Gene Therapy
MELBOURNE, Australia; and NEW YORK, May 23, 2019 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, will feature at the.
GlobeNewswire
Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference
NEW YORK and MELBOURNE, Australia, May 17, 2019 -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced an.
Simply Wall St.
What Kind Of Shareholders Own Mesoblast Limited (ASX:MSB)?
The big shareholder groups in Mesoblast Limited (ASX:MSB) have power over the company. Generally speaking, as a...
GlobeNewswire
FDA Agrees to Rolling Review of Mesoblast’s Biologics License Application for Its Cell Therapy in Children With Steroid-Refractory Acute Graft Versus Host Disease
ASX:MSB) global leader in cellular medicines for inflammatory diseases, announced today that the United States Food and Drug Administration (FDA) has agreed that Mesoblast can submit on a rolling basis a Biologics License Application (BLA) for its allogeneic cellular medicine remestemcel-L in children with steroid-refractory acute Graft Versus Host Disease (SR-aGVHD). Mesoblast will submit each module of the BLA to the FDA on a rolling basis as it is completed. The rolling process will provide opportunity for ongoing and frequent communication, and during this process the Company expects it will be able to adequately address any substantial matters raised by the FDA.